Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments

P Maiti, J Manna, GL Dunbar - Translational neurodegeneration, 2017 - Springer
Gradual degeneration and loss of dopaminergic neurons in the substantia nigra, pars
compacta and subsequent reduction of dopamine levels in striatum are associated with …

The role of microglia in retinal neurodegeneration: Alzheimer's disease, Parkinson, and glaucoma

AI Ramirez, R de Hoz, E Salobrar-Garcia… - Frontiers in aging …, 2017 - frontiersin.org
Microglia, the immunocompetent cells of the central nervous system (CNS), act as
neuropathology sensors and are neuroprotective under physiological conditions. Microglia …

α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease

CS Lindestam Arlehamn, R Dhanwani, J Pham… - Nature …, 2020 - nature.com
A diagnosis of motor Parkinson's disease (PD) is preceded by a prolonged premotor phase
with accumulating neuronal damage. Here we examined the temporal relation between α …

Parkinson disease

W Poewe, K Seppi, CM Tanner, GM Halliday… - Nature reviews Disease …, 2017 - nature.com
Parkinson disease is the second-most common neurodegenerative disorder that affects 2–
3% of the population≥ 65 years of age. Neuronal loss in the substantia nigra, which causes …

Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease

S George, NL Rey, T Tyson, C Esquibel… - Molecular …, 2019 - Springer
Background Cell-to-cell propagation of α-synuclein (α-syn) aggregates is thought to
contribute to the pathogenesis of Parkinson's disease (PD) and underlie the spread of α-syn …

Therapeutic approaches to target alpha-synuclein pathology

P Brundin, KD Dave, JH Kordower - Experimental neurology, 2017 - Elsevier
Starting two decades ago with the discoveries of genetic links between alpha-synuclein and
Parkinson's disease risk and the identification of aggregated alpha-synuclein as the main …

Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models

A Weihofen, YT Liu, JW Arndt, C Huy, C Quan… - Neurobiology of …, 2019 - Elsevier
Aggregation of α-synuclein (α-syn) is neuropathologically and genetically linked to
Parkinson's disease (PD). Since stereotypic cell-to-cell spreading of α-syn pathology is …

Emerging treatment approaches for Parkinson's disease

TB Stoker, KM Torsney, RA Barker - Frontiers in neuroscience, 2018 - frontiersin.org
Parkinson's disease (PD) is the second most common neurodegenerative disease,
manifesting as a characteristic movement disorder with a number of additional non-motor …

Intercellular spread of protein aggregates in neurodegenerative disease

AA Davis, CEG Leyns… - Annual review of cell and …, 2018 - annualreviews.org
Most neurodegenerative diseases are characterized by the accumulation of protein
aggregates, some of which are toxic to cells. Mounting evidence demonstrates that in …

Precision medicine for disease modification in Parkinson disease

AJ Espay, P Brundin, AE Lang - Nature reviews neurology, 2017 - nature.com
In this Perspectives article, Espay and colleagues argue that that the adoption of precision
medicine in Parkinson disease will require a revision of biomarker development efforts, with …